Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
A therosclerosis underlies the leading cause of death in industrialized countries. Atherosclerosis is a maladaptive, nonresolving chronic inflammatory disease that occurs predominantly at sites of disturbed laminar flow, notably, arterial branch points and bifurcations, of large and mediumsized arteries. Atherosclerosis is initiated by subendothelial buildup of apolipoprotein B–containing lipoproteins (in particular LDL [low-density lipoprotein]). LDL, particularly following oxidation, has properties of damage-associated molecular patterns and thereby provokes the activation of endothelial cells (ECs) and ensuing recruitment of blood-borne monocytes to the lesion. The Ly6C subpopulation of monocytes differentiates into macrophages. Serving to protect the organism against tissue damage, macrophages have developed plasticity to tailor the inflammatory responses. In short, macrophages have the capacity to trigger inflammation when necessary and to quell the inflammatory response when it is no longer required. In the atherosclerotic milieu, macrophages are predominantly polarized to an inflammatory phenotype. Lipid-loaded cells known as foam cells constitute a hallmark of atherosclerotic lesion, which can be detected at very early stages of atherosclerosis. The causal role for metabolic stress factors such as LDL, particularly oxidized LDL (oxLDL) and cholesterol, in promoting vascular inflammation and atherosclerosis has long been appreciated. However, the precise mechanism whereby metabolic stress elicits the proinflammatory status and induces atherogenesis remained unclear. When resolution of inflammation goes awry, nonresolving inflammation characterizes the atherosclerotic lesions. The mechanisms behind the nonresolving nature of vascular inflammation in the atherosclerotic lesion remain to be entirely defined. The inflammatory environment incurs apoptosis of intimal cells. Defective efferocytosis, a process by which phagocytic cells (predominantly macrophages) engulf the dead cells, promotes the formation of the necrotic core. Immune responses are further amplified by relentless production of damage-associated molecular patterns from necrotic cells in the advanced lesions. Innate immunity plays crucial roles in plaque initiation, progression, and rupture. It has been well established that the inflammasomes constitute an important component of innate immunity. The term inflammasome was first coined by Jurg Tschopp and his colleagues in 2002 to explain the mechanism for caspase-1 activation and interleukin-1b processing. To date, diverse inflammasomes have been discovered. Among the various inflammasomes identified, the nucleotide-binding oligomerization domain, leucine-rich repeat–containing receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome is best characterized. The groundbreaking findings that the NLRP3 inflammasome is a key player in orchestrating lipid-driven vascular inflammation and plays a fundamental role in the initiation and progression of atherogenesis are transforming the field of atherosclerosis. The focus of this review is on our current understanding of the role, regulation, and mechanisms of NLRP3 inflammasome activation in atherosclerosis. We will also discuss the therapeutic potential of NLRP3 inflammasome intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 8×
“NLRP3 can sense various types of the metabolic stress molecules, as exemplified by cholesterol crystals (CCs)(9) and oxLDL.(9,36) We will discuss how CCs and oxLDL drive atherosclerosis later.”
BackgroundResultInfluentialFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Inflammasomes: mechanism of assembly, regulation and signalling
Broz, P., & Dixit, V. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.58 · Cited by 3,500
Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Shi, J., Gao, W., & Shao, F. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.10.004 · Cited by 3,088 · cited 1×
“studies demonstrated that mature caspase-1 mediates proteolytic cleavage of gasdermin D, which in turn triggers pyroptosis through formation of membrane pores.(102) Therefore, caspase-1-dependent pyroptosis may very well partici-”
BackgroundCryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · cited 11×
“This finding demonstrated that the recruitment of small number of Tet2mutant cells in the plaque may be adequate to fuel atherosclerosis by promoting NLRP3/pro-interleukin-1bdriven vascular inflammation.84 It is reasonable to speculate that individuals carrying somatic mutations in Tet2 may respond much more favorably…”
BackgroundInfluentialMacrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Non-canonical inflammasome activation targets caspase-11
Kayagaki, N., Warming, S., Lamkanfi, M., Walle, L. V., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011) · Nature · doi:10.1038/nature10558 · Cited by 2,530
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · cited 13×
“Somatic mutation in TET2 is the first to be causally linked to atherosclerotic CVD.83,84 It has been appreciated that somatic mutations of additional genes, as exemplified by DNA methyltransferase 3a, additional sex combs like 1, and Janus kinase 2, may be implicated in atherosclerosis.83 Based upon their unique funct…”
BackgroundInfluentialCholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
Shi, C.-S., Shenderov, K., Huang, N.-N., Kabat, J., Abu-Asab, M., Fitzgerald, K. A., Sher, A., & Kehrl, J. H. (2012) · Nature Immunology · doi:10.1038/ni.2215 · Cited by 1,367
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295 · cited 2×
“and threonine kinase that is involved in mitosis, can directly bind NLRP3 and control NLRP3 oligomerization.(11) NEK7 appears to be a new component of the NLRP3 complex.”
BackgroundAn emerging role for neutrophil extracellular traps in noninfectious disease
Jorch, S. K., & Kubes, P. (2017) · Nature Medicine · doi:10.1038/nm.4294 · Cited by 1,244
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178 · cited 1×
“However, atherosclerotic plaques still undergo progression to a great extent in a large proportion of individuals whose blood cholesterol levels dramatically decline upon treatment with cholesterol-lowering drugs.(104) Thus, a large burden of residual disorder in individuals treated with statins demonstrates an unmet…”
BackgroundRajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039 · cited 1×
“Additionally, cathepsin B and potassium efflux are required for CC-triggered activation of the NLRP3 inflammasome.(67)”
BackgroundRecent insights into the cellular biology of atherosclerosis
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201412052 · Cited by 1,016 · cited 3×
“A therosclerosis underlies the leading cause of death in industrialized countries.(1) Atherosclerosis is a maladap-”
BackgroundInfluentialSheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. B., Becker, C. E., Ediriweera, H. N., Mullick, A. E., Golenbock, D. T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2639 · Cited by 935
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777
Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
Autophagy Links Inflammasomes to Atherosclerotic Progression
Razani, B., Feng, C., Coleman, T., Emanuel, R., Wen, H., Hwang, S., Ting, J. P., Virgin, H. W., Kastan, M. B., & Semenkovich, C. F. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.02.011 · Cited by 601
Mitochondria: diversity in the regulation of the NLRP3 inflammasome
Gurung, P., Lukens, J. R., & Kanneganti, T.-D. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.11.008 · Cited by 393
Fernández-Friera, L., Fuster, V., López-Melgar, B., Oliva, B., García-Ruiz, J. M., Mendiguren, J., Bueno, H., Pocock, S., Ibáñez, B., Fernández-Ortiz, A., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.024 · Cited by 378
van der Heijden, T., Kritikou, E., Venema, W., van Duijn, J., van Santbrink, P. J., Slütter, B., Foks, A. C., Bot, I., & Kuiper, J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309575 · Cited by 348 · cited 6×
“45 Through this process, cholesterol is transported from peripheral tissues back to the liver, followed by excretion into bile and feces.46 It is known that HDL can partially dissolve CCs.47 Deficiency of ABCA1/G1 in myeloid cells induces significant accumulation of cholesterol in macrophages and ensuing NLRP3 inflamm…”
BackgroundInfluentialCholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis
Westerterp, M., Fotakis, P., Ouimet, M., Bochem, A. E., Zhang, H., Molusky, M. M., Wang, W., Abramowicz, S., la Bastide-van Gemert, S., Wang, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032636 · Cited by 331
Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A. T., Kisielow, J., Hersberger, M., Yamamoto, M., Bachmann, M. F., & Kopf, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041316 · Cited by 300 · cited 3×
“Mechanistically, CCs trigger Nrf2-dependent interleukin-1b expression in macrophages in a manner that is dependent on NLRP3 inflammasome-mediated caspase-1 activation.(68) Importantly, the NLRP3 inflammasome integrates inflammation and oxidative stress, both of which are known to contribute significantly to atherogene…”
BackgroundTet2 restrains inflammatory gene expression in macrophages
Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A., & Rauh, M. J. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.08.001 · Cited by 295
Xiao, H., Lu, M., Lin, T. Y., Chen, Z., Chen, G., Wang, W.-C., Marin, T., Shentu, T.-P., Wen, L., Gongol, B., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002714 · Cited by 257
Cited by
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Bouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022) · Biology · doi:10.3390/biology11020300 · Cited by 87
Chiu, Y.-C., Chu, P.-W., Lin, H.-C., & Chen, S.-K. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101166 · Cited by 18
Metadata
- Authors
- Jin, Y., & Fu, J.
- Venue
- Journal of the American Heart Association
- Published
- 2019-06-18
- Volume
- 8
- Issue
- 12
- Pages
- e012219-e012219
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2950956897
- Cited by
- 148
- References
- 31
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.